Welcome to our dedicated page for BIOSTEM TECHNOLOGIES NEW news (Ticker: $BSEM), a resource for investors and traders seeking the latest updates and insights on BIOSTEM TECHNOLOGIES NEW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOSTEM TECHNOLOGIES NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOSTEM TECHNOLOGIES NEW's position in the market.
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) appoints Patrick Daly to its Board of Directors. Daly brings extensive industry experience and relationships in the Biomaterials and MedTech market segments. He has a successful track record in operations, strategy, sales, marketing, fundraising, and partnership-building.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) announces that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2™, in all Medicare Administrative Contractors (MAC) regions, effective Jan 1, 2024. The company exclusively commercializes AmnioWrap2™ through Venture Medical LLC, an innovative solutions provider in the U.S. wound care market. The CEO emphasized the significance of this achievement, highlighting the benefit it brings to Medicare patients across the United States. The President of Venture Medical LLC expressed eagerness to provide more clinical results and support formal clinical studies, expecting broad product adoption throughout the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.43%
Tags
-
News
Rhea-AI Summary
BioStem Technologies Inc. (OTC:BSEM) appoints Mr. Thomas J. Dugan as Chairman of the Board. Mr. Dugan brings extensive experience in wound care and surgical fields, having transformed businesses and established new market opportunities. BioStem CEO, Jason Matuszewski, looks forward to benefiting from Mr. Dugan's leadership and industry experience to optimize value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) reported financial results for the quarter ended September 30, 2023, showcasing a remarkable year of growth and milestones. The company's earnings call will highlight significant achievements, including securing a CMS Q code for VENDAJE AC®, a successful capital raise, and crucial clinical trials for diabetic foot ulcers. The quarter also saw game-changing partnerships with NovaBay Pharmaceuticals and Venture Medical, reflecting BioStem's dedication to transforming regenerative medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC:BSEM) announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® for advanced wound care, effective January 1st, 2024. This code will ensure broader access and reimbursement pathways for the product, marking a significant milestone for the company's portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.8%
Tags
-
News
Rhea-AI Summary
BioStem Technologies Inc. plans to release its third quarter 2023 financial results on Tuesday, November 14, 2023. The company will host a conference call and webcast to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
Rhea-AI Summary
BioStem Technologies Inc. has closed an oversubscribed private placement of common stock, raising $2 million in gross proceeds. The placement consisted of 1,337,000 units at a price of $1.50 per unit. The company plans to use the net proceeds to complete clinical trials, expand brand awareness and product distribution, and execute product pipeline plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. has announced the opening of the first site for its clinical trial evaluating the Vendaje tissue allograft in the treatment of diabetic foot ulcers. The trial aims to showcase the effectiveness of the product and the advantages of BioStem's proprietary BioREtain process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
-
News
Rhea-AI Summary
BioStem Technologies Inc. to showcase its Vendaje® and AmnioWrap2TM portfolios at the 2023 Symposium on Advanced Wound Care Fall Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
Rhea-AI Summary
BioStem Technologies hails the withdrawal of final local coverage determinations for cellular and/or tissue-based products for DFU and VLU, which positively impacts patient treatment options. This is an important milestone for BioStem as they work towards delivering cutting-edge wound care management products and addressing a significant market opportunity, adding long-term value for shareholders. BioStem also received IRB approval for a clinical study on the utilization and effects of their VendajeⓇ wound care products in DFU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
BIOSTEM TECHNOLOGIES NEW
OTC:BSEM
BSEM Rankings
BSEM Stock Data
123.93M
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Pompano Beach